Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leukotriene A-4 hydrolase (LTA4H) is a bifunctional zinc metalloenzyme that catalyzes the conversion of leukotriene A4 (LTA4) to leukotriene B4 (LTB4), a potent pro-inflammatory mediator. It also exhibits aminopeptidase activity, cleaving N-terminal arginines from peptides. It plays a critical role in inflammatory signaling pathways and is implicated in various inflammatory diseases, making it a therapeutic target for controlling excessive inflammation. Inhibitors of LTA4H offer potential benefits for treating inflammatory conditions.
Inhibition of LTA4H, blocking the conversion of LTA4 to LTB4.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leukotriene A-4 Hydrolase.